We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.13 | 11.25% | 11.125 | 10.75 | 11.50 | 11.125 | 9.875 | 10.00 | 1,642,507 | 15:25:22 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -8.62 | 103.17M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/9/2023 08:28 | just to put that into context ......... if i had been wrong it would have cost me £130,000 of capital as big mama says Money talks LOL | inanaco | |
19/9/2023 08:21 | and scancell did it as a standalone .......... | inanaco | |
19/9/2023 08:18 | . In a Phase 1/2 clinical trial, 14 out of 16 resected patients (89%) survived for more than 5 years following vaccination with SCIB1. The original Phase 2 study was designed to assess whether the addition of SCIB1 treatment to pembrolizumab results in an improvement in patient outcomes for patients with metastatic disease. | marcusl2 | |
19/9/2023 08:15 | For any newbies, Scib is off the shelf. Merck / Moderna is personalised. iScib with Avidimab will be a further improvement and cover ALL patients. | marcusl2 | |
19/9/2023 08:14 | Marcus scancell from memory was 88% in the same setting "resected" | inanaco | |
19/9/2023 08:14 | Plasbryn - IMO the endpoint for the impact of this data will not be diminished in any way by the release today of this RNS . . . an alternative view would be that matters are now nicely primed for Prof. Lindy at Cicon Milan - Scancell are ready to turn on the afterburners later this week. | torquayfan | |
19/9/2023 08:13 | Plenty of the big boys will want Immunobody and Avidimab. Don`t forget about Moditope and the Glymabs !! | marcusl2 | |
19/9/2023 08:11 | Moderna and Merck’s Cancer Vaccine Cuts Risk of Recurrence or Death 44% in Late-Stage, High-Risk Melanoma After Resection Scancell... Key Highlights -- SCOPE trial surpasses its first milestone with an 82% response rate -- To our knowledge no other combination has achieved this response rate with doublet checkpoint inhibitors in unresectable metastatic melanoma ( one is resected the other unresected ) | marcusl2 | |
19/9/2023 08:08 | Vastly derisked data here. Very nice. Should really move on higher. Half the mcap of AVCT and more advanced?Of course you get sell on news brigade but really good update. | babbler | |
19/9/2023 08:06 | Plasbryn,They were always going to have to update the market on the SBIB data - and indeed they said they would.Question is, will there be a Modi-1 update too?On the "market price" aspect, we are getting closer to having a properly-informed market. The last few months are now being proven to have been irrelevant, as I'd pointed out - simply because nobody who was buying or selling knew the trial data. | markingtime | |
19/9/2023 08:01 | 10 years of Scib1 ....... no risk which one has failed posts LOL devastating news for the "this is risky brigade" i also told you SCIB1 is the backstop ........... and explained why | inanaco | |
19/9/2023 07:58 | Ruck - re. "I wonder if the RNS had to be brought forward because the cat was out the bag? " Good point but I guess it would be hard to contain news of this significance. I doubt that the endpoint for the 'impact' will be any lower because of this RNS today. | torquayfan | |
19/9/2023 07:57 | yes that will be a shocker for merck and moderna | inanaco | |
19/9/2023 07:56 | Move over Merck and mRNA, here comes Lindy | marcusl2 | |
19/9/2023 07:55 | Who said anything about £15-20mn, Bermuda?Clearly I was talking about number of shares. | markingtime | |
19/9/2023 07:54 | firestarter ....... you are not very good at this are you | inanaco | |
19/9/2023 07:54 | News clearly known over the weekend given immediate buying on open. However, news was only known to a small section of the market - rise should continue. | nigelpm | |
19/9/2023 07:53 | i am sure you would like my holding at 7.59 am .... ruck | inanaco | |
19/9/2023 07:53 | Sell on news as this has already risen yesterday 50% nowExpect the insiders to dump | firestarter1 | |
19/9/2023 07:52 | trinity will need to revalue | inanaco | |
19/9/2023 07:51 | "go all in verified"We are a long way from that lol. | ruckrover | |
19/9/2023 07:51 | A stunning RNS on what is a difficult cancer to control. This is top draw research and now what looks certain delivery. | rogerbridge | |
19/9/2023 07:51 | Ivy is colin from accounts | inanaco | |
19/9/2023 07:50 | Ruck - re. your objection - "And all you can do is gloat?" . . . would it be fair to say "And all YOU can do is carp?" ?? Anyway - who is 'Colin from Accounts' ? | torquayfan |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions